CoChat

ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma

Open access
Arrieta, Víctor A., Chen, Andrew X., Kane, J. Robert, Kang, Seong Jae, Kassab, Cynthia, Dmello, Crismita, Zhao, Junfei, Burdett, Kirsten B., Upadhyayula, Pavan S., Lee-Chang, Catalina, Shilati, Joseph, Jaishankar, Dinesh, Chen, Li, Gould, Andrew, Zhang, Daniel, Yuan, Jinzhou, Zhao, Wenting, Ling, Xiaoyang, Burks, Jared K., Laffleur, Brice, Amidei, Christina, Bruce, Jeffrey N., Lukas, Rimas V., Yamaguchi, Jonathan T., Cieremans, David, Rothschild, Gerson, Basu, Uttiya, McCord, Matthew, Brat, Daniel J., Zhang, Hui, Cooper, Lee A. D., Zhang, Bin, Sims, Peter, Cloughesy, Tim F., Prins, Robert, Canoll, Peter, Stupp, Roger, Heimberger, Amy B., Horbinski, Craig, Iwamoto, Fabio M., Rabadan, Raul, Sonabend, Adam M. · 2021 · Nature Cancer
Cited by 107

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Only a subset of recurrent glioblastoma (rGBM) responds to anti-PD-1 immunotherapy. Previously, we reported enrichment of BRAF/PTPN11 mutations in 30% of rGBM that responded to PD-1 blockade. Given that BRAF and PTPN11 promote MAPK/ERK signaling, we investigated whether activation of this pathway is associated with response to PD-1 inhibitors in rGBM, including patients that do not harbor BRAF/PTPN11 mutations. Here we show that immunohistochemistry for ERK1/2 phosphorylation (p-ERK), a marker of MAPK/ERK pathway activation, is predictive of overall survival following adjuvant PD-1 blockade in two independent rGBM patient cohorts. Single-cell RNA-sequencing and multiplex immunofluorescence analyses revealed that p-ERK was mainly localized in tumor cells and that high-p-ERK GBMs contained tumor-infiltrating myeloid cells and microglia with elevated expression of MHC class II and associated genes. These findings indicate that ERK1/2 activation in rGBM is predictive of response to PD-1 blockade and is associated with a distinct myeloid cell phenotype. In two cohorts of patients with glioblastoma who received anti-PD-1, Sonabend and colleagues show that ERK1/2 phosphorylation, detected by immunohistochemistry, provides a biomarker for MAPK/ERK pathway activity and better survival on this therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s43018-021-00260-2

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 107

Metadata

Authors
Arrieta, V. A., Chen, A. X., Kane, J. R., Kang, S. J., Kassab, C., Dmello, C., Zhao, J., Burdett, K. B., Upadhyayula, P. S., Lee-Chang, C., Shilati, J., Jaishankar, D., Chen, L., Gould, A., Zhang, D., Yuan, J., Zhao, W., Ling, X., Burks, J. K., Laffleur, B., Amidei, C., Bruce, J. N., Lukas, R. V., Yamaguchi, J. T., Cieremans, D., Rothschild, G., Basu, U., McCord, M., Brat, D. J., Zhang, H., Cooper, L. A. D., Zhang, B., Sims, P., Cloughesy, T. F., Prins, R., Canoll, P., Stupp, R., Heimberger, A. B., Horbinski, C., Iwamoto, F. M., Rabadan, R., & Sonabend, A. M.
Venue
Nature Cancer
Published
2021-11-29
Volume
2
Issue
12
Pages
1372-1386
ISSN
2662-1347 (ISSN-L)
OpenAlex
W3215684331
Cited by
107
References
25
FWCI
8.29
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. https://app.cochat.ai/papers/10.1038/s43018-021-00260-2
The paper
Arrieta, V. A., Chen, A. X., Kane, J. R., Kang, S. J., Kassab, C., Dmello, C., Zhao, J., Burdett, K. B., Upadhyayula, P. S., Lee-Chang, C., Shilati, J., Jaishankar, D., Chen, L., Gould, A., Zhang, D., Yuan, J., Zhao, W., Ling, X., Burks, J. K., . . . Sonabend, A. M. (2021). ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nature Cancer. https://doi.org/10.1038/s43018-021-00260-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.